Avosentan
CAS: 290815-26-8
Ref. 3D-QLA81526
| 5mg | A consultar | |
| 10mg | A consultar | |
| 25mg | A consultar | |
| 50mg | A consultar | |
| 100mg | A consultar |
Información del producto
- Ro 67-0565
- Spp 301
Avosentan is an endothelin receptor antagonist that has been shown to be a long-term effective treatment for chronic kidney disease in diabetic patients. It blocks the binding of endothelin-A to its receptor, which prevents the constriction and dilation of blood vessels. Avosentan has been shown to increase renal function by inhibiting tubulointerstitial injury and reducing the rate of progression of chronic kidney disease. This drug also has a positive effect on congestive heart failure, as it increases cardiac output and reduces afterload. Avosentan also stimulates growth factor production in heart tissue, which may account for some of its positive effects on cardiac function.
Propiedades químicas
Consulta técnica sobre: 3D-QLA81526 Avosentan
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
